Risk Factors for Progressive Disease After Immune Checkpoint Inhibitor Therapy in Head and Neck Squamous Cell...

Area of Science:

• Oncology
• Immunotherapy
• Head and Neck Cancer Research

Background:

• Investigating clinical features of patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
• Focusing on patients who experienced progressive disease (PD) after receiving immune checkpoint inhibitor (ICI) therapy.

Purpose of the Study:

• To analyze clinical factors associated with treatment outcomes in R/M HNSCC patients post-ICI therapy.
• To identify predictors of progressive disease and overall survival in this patient cohort.

Main Methods:

• Retrospective analysis of 256 R/M HNSCC patients from 11 medical centers.
• Evaluation of associations between clinical factors and treatment outcomes: best response, overall survival, and progression-free survival.

Main Results:

• Objective response rate was 19.5%; 50.4% experienced progressive disease (PD).
• High neutrophil-to-lymphocyte ratio (NLR > 4) and large tumor size (> 40 mm) were significant risk factors for PD.
• High NLR, poor performance status (ECOG PS 2-3), and large tumor size independently predicted poor overall survival.

Conclusions:

• Elevated NLR and larger tumor size are key indicators of higher risk for PD during ICI therapy.
• These factors also correlate with diminished overall survival in R/M HNSCC patients undergoing ICI treatment.